Home › Leucemia mieloide acuta › Maryland
Studi clinici su Leucemia mieloide acuta nello stato di Maryland
31 studi su Leucemia mieloide acuta cercano partecipanti presso sedi nello stato di Maryland.
Città nello stato di Maryland
Testo ufficiale dello studio (inglese)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoFase 1
Età da 18 a 120 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06904066Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- e altri 10
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Center for Cancer and Blood Disorders, Bethesda
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
In reclutamentoFase 1 iniziale
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06398457Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Walter Reed National Military Medical Center, Bethesda
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT05554406A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Johns Hopkins University, Baltimore
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- e altri 1
In reclutamentoFase 3
6 Months – 21 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- John Hopkins School of Medicine, Baltimore
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06824168The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoFase 1/2Volontari sani benvenuti
Età da 12 a 120 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT05436418Longitudinal Studies of Patient With FPDMM
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoStudio osservazionaleVolontari sani benvenuti
1 Day – 100 Years · Tutti i sessi · Aggiornato il 11 set 2026 · NCT03854318A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- The Center for Cancer and Blood Disorders, Bethesda
In reclutamentoStudio osservazionale
Età 0 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT07154823Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Baltimore MD-UMGCCC, Baltimore
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06652438Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Baltimore MD-UMGCCC, Baltimore
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT07223814A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Maryland/Greenebaum Cancer Center, Baltimore
In reclutamentoFase 1
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
In reclutamentoFase 1/2
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoFase 1
Età da 3 a 35 · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT02390752Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
- Tania Jain, MD, Baltimore
In reclutamentoFase 1
6 Months – 80 Years · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT02203903Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 18 a 120 · Tutti i sessi · Aggiornato il 23 lug 2026 · NCT05588154Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoStudio osservazionaleVolontari sani benvenuti
1 Day – 120 Years · Tutti i sessi · Aggiornato il 23 lug 2026 · NCT05350748Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Maryland Medical Center (UMMC), Baltimore
In reclutamentoFase 3
Età da 18 a 75 · Tutti i sessi · Aggiornato il 17 lug 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Johns Hopkins, Baltimore
- Nih/Niaid, Bethesda
- Nih/Nhlbi, Bethesda
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- National Institutes of Health Clinical Center, Bethesda
In reclutamentoStudio osservazionale
1 Month – 120 Years · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT07019155CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 lug 2026 · NCT04050280Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT04068597A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Johns Hopkins School of Medicine, Baltimore
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mar 2026 · NCT05735184Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Johns Hopkins University, Baltimore
In reclutamentoVolontari sani benvenuti
Età da 18 a 120 · Tutti i sessi · Aggiornato il 25 lug 2025 · NCT05237258Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.